Sudarshan Pharma Q1 Results: Net profit up 42% to ₹5.61 crore
Sudarshan Pharma Industries posted a 41.6% YoY rise in Q1FY27 net profit to ₹5.61 crore, driven by 20.1% revenue growth and margin expansion. Gross profit margin improved to 14.13% from 11.05%, while EBITDA margin rose to 9.81%. The company highlighted strategic expansions in regulated export markets and new API manufacturing capabilities in Hyderabad.
*this image is generated using AI for illustrative purposes only.
Sudarshan Pharma Industries reported a significant improvement in profitability for the first quarter of FY27, with net profit after tax (PAT) rising 41.6% year-on-year to ₹5.61 crore. The pharmaceutical and specialty chemicals manufacturer achieved this growth against a backdrop of expanding revenues and improving operational margins, marking a strong start to the fiscal year following a full-year PAT growth of 102% in FY26.
Revenue from operations increased 20.1% to ₹174.41 crore in June 2026, compared to ₹145.26 crore in the same period last year. This top-line growth was accompanied by a notable expansion in gross profit margin, which widened to 14.13% from 11.05% in Q1FY26. The company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) rose 39.7% to ₹17.11 crore, with the EBITDA margin improving to 9.81% from 8.43% previously.
Financial Performance
The consolidated financial results for the quarter highlight consistent growth across key metrics compared to the prior year period. Finance costs remained elevated at ₹8.20 crore, up from ₹5.96 crore in Q1FY26, reflecting higher borrowing levels to support expansion initiatives.
| Metric: | Q1FY27 | Q1FY26 | Change |
|---|---|---|---|
| Revenue from Operations: | ₹174.41 crore | ₹145.26 crore | +20.1% |
| Gross Profit Margin: | 14.13% | 11.05% | +308 bps |
| EBITDA: | ₹17.11 crore | ₹12.25 crore | +39.7% |
| EBITDA Margin: | 9.81% | 8.43% | +138 bps |
| Net Profit After Tax: | ₹5.61 crore | ₹3.96 crore | +41.6% |
For the full year FY26, Sudarshan Pharma logged revenue of ₹703.05 crore, a 39.2% increase over FY25’s ₹505.05 crore. Full-year PAT surged 102% to ₹23.41 crore from ₹11.59 crore in the preceding year, demonstrating sustained operational momentum throughout the fiscal cycle.
What the Numbers Show
A critical observation from the balance sheet is the substantial increase in leverage alongside revenue growth. Short-term borrowings rose sharply to ₹255.11 crore as on March 31, 2026, from ₹160.27 crore a year earlier. Concurrently, long-term borrowings increased to ₹38.37 crore from ₹10.46 crore. This debt accumulation appears linked to capital expenditure, as property, plant, and equipment assets nearly tripled to ₹96.03 crore from ₹29.91 crore. While revenue grew robustly, the finance cost of ₹8.20 crore in Q1FY27 consumed approximately 148% of the operating EBITDA, indicating that debt servicing remains a significant pressure point on bottom-line retention despite margin improvements.
Strategic Initiatives
The company outlined its strategic focus for FY27-28, emphasizing vertical integration and expansion into regulated markets. Sudarshan Pharma aims to strengthen its presence in semi-regulated and regulated segments, targeting an export turnover of at least ₹100 crore in FY27. The firm plans to increase its range of high-value Active Pharmaceutical Ingredients (APIs) to boost exports to Europe and the USA.
Key operational developments include:
- Hyderabad Unit: A new bulk drug and intermediate manufacturing facility has secured Good Manufacturing Practice (GMP) certification for API intermediates and ISO 9001:2015 for quality management. The unit holds patent rights for several key starting materials.
- R&D Collaboration: A strategic partnership with Amity University focuses on nanotechnology, pharmaceutical R&D, and patent filings, led by Dr. William Selvamurthy.
- Product Portfolio: Expansion into oncology APIs such as Gemcitabine and Olaparib, alongside new chemical sector products like 1,4-Dioxane and Acetonitrile.
The investor presentation, submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, highlights the company’s efforts to mitigate supply chain dependencies on China by developing domestic manufacturing capabilities for specialty chemicals and intermediates.
Historical Stock Returns for Sudarshan Pharma Industries
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.72% | +15.42% | -6.80% | +43.77% | +16.57% | +437.18% |
How will Sudarshan Pharma manage the rising finance costs, which currently exceed operating EBITDA, as it continues to service its increased debt load from recent capex?
What specific regulatory hurdles or timeline delays might impact the company's goal of achieving ₹100 crore in export turnover for FY27?
To what extent will the new Hyderabad unit's GMP-certified production capacity contribute to reducing supply chain dependencies on China within the next 12 months?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
